TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07589205: A Phase 1, Multi-Center, Open-Label Study Evaluating IBI3028 Treatment in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 493 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07589205 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07589205 Rescue Dossier →